The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adachi, T.
Right arrow Articles by Alam, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adachi, T.
Right arrow Articles by Alam, R.
The Journal of Immunology, 1999, 163: 939-946.
Copyright © 1999 by The American Association of Immunologists

A Novel Lyn-Binding Peptide Inhibitor Blocks Eosinophil Differentiation, Survival, and Airway Eosinophilic Inflammation1, 2

Tetsuya Adachi, Susan Stafford, Sanjiv Sur and Rafeul Alam3

Department of Internal Medicine, Division of Allergy and Immunology, University of Texas Medical Branch, Galveston, TX 77555

Receptor antagonists block all receptor-coupled signaling pathways indiscriminately. We introduce a novel class of peptide inhibitors that is designed to block a specific signal from a receptor while keeping other signals intact. This concept was tested in the model of IL-5 signaling via Lyn kinase. We have previously mapped the Lyn-binding site of the IL-5/GM-CSF receptor common ß (ßc) subunit. In the present study, we designed a peptide inhibitor using the Lyn-binding sequence. The peptide was N-stearated to enable cellular internalization. The stearated peptide blocked the binding of Lyn to the ßc receptor and the activation of Lyn. The lipopeptide did not affect the activation of Janus kinase 2 or its association with ßc. The inhibitor blocked the Lyn-dependent functions of IL-5 in vitro (e.g., eosinophil differentiation from stem cells and eosinophil survival). It did not affect eosinophil degranulation. When applied in vivo, the Lyn-binding peptide significantly inhibited airway eosinophil influx in a mouse model of asthma. The lipopeptide had no effect on basophil histamine release or on the proliferation of B cells and T cells. To our knowledge, this is the first report on an inhibitor of IL-5 that blocks eosinophil differentiation, survival, and airway eosinophilic inflammation. This novel strategy to develop peptide inhibitors can be applied to other receptors.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
S.-J. E. Beavitt, K. W. Harder, J. M. Kemp, J. Jones, C. Quilici, F. Casagranda, E. Lam, D. Turner, S. Brennan, P. D. Sly, et al.
Lyn-Deficient Mice Develop Severe, Persistent Asthma: Lyn Is a Critical Negative Regulator of Th2 Immunity
J. Immunol., August 1, 2005; 175(3): 1867 - 1875.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Y. Niv, H. Rubin, J. Cohen, L. Tsirulnikov, T. Licht, A. Peretzman-Shemer, E. Cna'an, A. Tartakovsky, I. Stein, S. Albeck, et al.
Sequence-based Design of Kinase Inhibitors Applicable for Therapeutics and Target Identification
J. Biol. Chem., January 9, 2004; 279(2): 1242 - 1255.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
X. Zhu, B. Jacobs, E. Boetticher, S. Myou, A. Meliton, H. Sano, A. T. Lambertino, N. M. Munoz, and A. R. Leff
IL-5-induced integrin adhesion of human eosinophils caused by ERK1/2-mediated activation of cPLA2
J. Leukoc. Biol., November 1, 2002; 72(5): 1046 - 1053.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
Z. Allakhverdi, M. Allam, and P. M. Renzi
Inhibition of Antigen-induced Eosinophilia and Airway Hyperresponsiveness by Antisense Oligonucleotides Directed against the Common beta Chain of IL-3, IL-5, GM-CSF Receptors in a Rat Model of Allergic Asthma
Am. J. Respir. Crit. Care Med., April 1, 2002; 165(7): 1015 - 1021.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Ogura, H. Ueda, K. Hosohara, R. Tsuji, Y. Nagata, S.-i. Kashiwamura, and H. Okamura
Interleukin-18 stimulates hematopoietic cytokine and growth factor formation and augments circulating granulocytes in mice
Blood, October 1, 2001; 98(7): 2101 - 2107.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J.C. Kips, K.G. Tournoy, and R.A. Pauwels
New anti-asthma therapies: suppression of the effect of interleukin (IL)-4 and IL-5
Eur. Respir. J., March 1, 2001; 17(3): 499 - 506.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Lach-Trifilieff, K. Menear, E. Schweighoffer, V. L. J. Tybulewicz, and C. Walker
Syk-deficient eosinophils show normal interleukin-5-mediated differentiation, maturation, and survival but no longer respond to Fcgamma R activation
Blood, October 1, 2000; 96(7): 2506 - 2510.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Adachi, B. K. Choudhury, S. Stafford, S. Sur, and R. Alam
The Differential Role of Extracellular Signal-Regulated Kinases and p38 Mitogen-Activated Protein Kinase in Eosinophil Functions
J. Immunol., August 15, 2000; 165(4): 2198 - 2204.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Du, Y. M. Alsayed, F. Xin, S. J. Ackerman, and L. C. Platanias
Engagement of the CrkL Adapter in Interleukin-5 Signaling in Eosinophils
J. Biol. Chem., October 13, 2000; 275(42): 33167 - 33175.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1999 by The American Association of Immunologists, Inc. All rights reserved.